NCT06097962 2026-03-20
Safety and Efficacy of NK510 to Treat NSCLC
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
Clinical Trials
5 trialsNCT05700448 2026-02-05
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals
Phase 3 Not yet recruiting
NCT06617416 2025-03-12
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Akeso
Phase 3 Recruiting
NCT05131438 2023-03-27
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
EQRx International, Inc.
No longer available
NCT04194801 2023-02-06
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 1/2 Completed